In this webinar, Robert Lowrey and David Siderovski will discuss novel AI-driven drug discovery approaches targeting ...

The GPCR field is experiencing a renaissance, driven by renewed investment, clinical progress, and next-generation technologies unlocking hundreds of previously untargeted receptors. With rapid ...

Background: Human Relaxin-2 (RLN2) signals via G-protein coupled receptor (GPCR) relaxin family peptide receptor 1 (RXFP1), and exerts vasodilatory, anti-inflammatory, and anti-fibrotic effects in the ...

Collaboration Combines Best-in-Class Biology with Agile AI and Chemistry Automation for Rapid Discovery of Better Molecules for Highly Valuable G Protein-Coupled Receptor (GPCR) Targets MENLO PARK, ...

G protein-coupled receptors (GPCRs) are one of the most desirable and challenging target classes in drug discovery, as their mutation can lead to a wide range of diseases such as cancer, ...

The global G-protein coupled receptors market size surpassed US$ 3.86 in 2024, rise to US$ 4.06 billion in 2025, and is expected to hit around US$ 6.37 billion by 2034. The market is growing at a CAGR ...

Join this webinar to discover how GPCR functional, cell-based assays determine off-target effects, reveal safety issues, and define drug mechanism of action to ultimately evaluate the therapeutic ...

When we hear that a person has quirks, we expect to be charmed. But when we hear that a cell-based assay has quirks, we expect to be frustrated. Quirks in cell-based assays tend to complicate drug ...